1. Clinical Overview

Molecule: Mazdutide (IBI362) — novel once-weekly synthetic dual-receptor peptide agonist of GLP-1R and GCGR.

Classification: GLP-1/glucagon dual agonist • Investigational anti-obesity therapeutic • Emerging alternative to tirzepatide and survodutide

Simultaneously suppresses appetite/food intake, stimulates energy expenditure via glucagon pathway, enhances glycemic control, lipid metabolism, and visceral fat reduction.

2. Mechanisms of Action

2.1 GLP-1R Agonism

Glucose-dependent insulin secretion, glucagon secretion inhibition, delayed gastric emptying, satiety promotion, appetite reduction.

2.2 GCGR Agonism

Hepatic lipid oxidation, thermogenesis and energy expenditure, fat store mobilization.

2.3 Dual-Synergistic Activity

GLP-1 mediates caloric reduction while glucagon drives fat loss and energy burn. May offer superior body composition preservation vs GLP-1 monotherapy.

3. Evidence Summary — Clinical Trials

3.1 Phase 1 & 2 Highlights

Up to 15.4% total body weight loss over 20–32 weeks (comparable to tirzepatide). Substantial reduction in visceral adipose tissue and waist circumference. Improvements in fasting glucose, insulin, HbA1c, and HOMA-IR.

3.2 Body Composition

Favorable lean mass retention. Enhanced fat oxidation (respiratory quotient).

3.3 Lipid & Inflammatory Markers

Reduced triglycerides and LDL. Modest improvements in CRP and adiponectin.

3.4 NAFLD/NASH Implications

MRI-PDFF data shows reduced liver fat fraction. Anti-steatotic effect supports hepatic protocol exploration.

4. Clinical Protocols

Route: SC (abdomen, thigh, arm) • Once-weekly
Titrate gradually to minimize GI effects — avoid escalation with unresolved nausea/vomiting

Dose Titration Schedule

Week	Dose (mg/week)
1–4	1.5 mg
5–8	3.0 mg
9–12	4.5 mg
13+	6.0 mg maintenance (max: 9.0 mg)

5. Clinical Integration Strategies

+ CJC-1295/Ipamorelin: Lean mass retention + GH/IGF-1 axis support during rapid weight loss
+ 5-Amino-1MQ or MOTS-c: Visceral adiposity + mitochondrial optimization
+ SLU-PP-332: Enhanced thermogenesis, UCP-1 activation
+ REVIVE™ AM or NAD+ Stack: Liver fat reduction + glucose/insulin sensitivity

6. Clinical Archetypes

Archetype A — Obesity / Body Recomposition

Mazdutide 6.0 mg weekly + CJC/Ipamorelin + Resistance training emphasis

Archetype B — Metabolic Syndrome / Prediabetes

Mazdutide 3.0–4.5 mg + MOTS-c (3×/week) + Berberine, omega-3s

Archetype C — NASH/NAFLD Candidate

Mazdutide + SLU-PP-332 or SS-31 + REVIVE™ mitochondrial stack

7. Decision Tree for Clinical Use

Scenario	Mazdutide Role
Obesity with insulin resistance	Strong candidate
Visceral adiposity & metabolic inflexibility	Ideal candidate
History of GLP-1 intolerance	Use with caution
Desire for lean mass preservation	Consider CJC-1295 co-therapy
Previous pancreatitis	Contraindicated

8. Safety, Side Effects & Monitoring

Common Side Effects

Nausea, vomiting, constipation, appetite suppression, fatigue.

Contraindications

Pregnancy and breastfeeding
Personal/family history of medullary thyroid cancer or MEN2
History of pancreatitis

Monitoring

Baseline and periodic CMP
HbA1c, insulin, fasting glucose q12 weeks
Weight, waist circumference, liver function tests

Legal Disclaimer

This document is provided solely for educational and informational purposes. Mazdutide and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Mazdutide Clinical Reference Guide

1. Xu, Y., et al. (2023). Mazdutide (IBI362) for Obesity: Phase 2 Trial. Nature Medicine, 29(5), 1020–1028.

2. Chen, X., et al. (2021). Mazdutide reduces body weight and liver fat in T2D: Phase 1b. Diabetes Obes Metab, 23(12), 2623–2632.

3. Innovent Biologics. (2023). Mazdutide (IBI362) Clinical Pipeline & Results Summary. Company Report.

4. Lee, M., et al. (2023). Dual incretin/glucagon therapeutics in obesity and diabetes. Trends Pharmacol Sci, 44(3), 180–192.

5. Yu, X., et al. (2022). IBI362 on weight loss and glycemic control: Phase 1. eClinicalMedicine, 50, 101520.

6. Xu, Y., et al. (2022). MRI-PDFF liver fat reduction from Mazdutide. Hepatology Research, early access.

7. Drucker, D. J. (2021). GLP-1 and glucagon co-agonism: Metabolic benefits. Cell Metabolism, 33(3), 479–496.